SCHEMBL4209482

SCHEMBL4209482

COc1ccc(NS(=O)(=O)c2cc(C(F)(F)F)ccc2F)c2c1C[C@@H](N(C)C)CO2

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.46
QRFPR Q96P65 1/20 0.46
ERAP1 Q9NZ08 4/20 0.41
ERAP2 Q6P179 2/20 0.41
ALPL P05186 2/20 0.39
KIF11 P52732 1/20 0.37
SCN9A Q15858 1/20 0.37
BRD4 O60885 3/20 0.36
TRIM24 O15164 1/20 0.36
HTR1A P08908 3/20 0.36
SLC6A4 P31645 3/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4201193 0.90 HTR6 (0.47) HTR6QRFPRERAP1ERAP2ALPL
SCHEMBL4202949 0.90 HTR6 (0.48) HTR6QRFPRALPLHTR1ASLC6A4
SCHEMBL4199245 0.89 HTR6 (0.49) HTR6QRFPRERAP1ERAP2KIF11
SCHEMBL4212688 0.88 HTR6 (0.47) HTR6QRFPRHTR1ASLC6A4
SCHEMBL4211828 0.86 KMT2A (0.45) HTR6QRFPRKIF11CYP3A4CYP2D6
SCHEMBL4207623 0.86 HTR6 (0.45) HTR6QRFPR
SCHEMBL4204701 0.86 PSEN1 (0.48) HTR6QRFPRERAP1ERAP2KIF11
SCHEMBL4204574 0.85 NPSR1 (0.45) HTR6QRFPRCYP3A4CYP2D6PSEN1
SCHEMBL4202391 0.85 HTR6 (0.48) HTR6QRFPRHTR1ASLC6A4
SCHEMBL4203313 0.85 HTR6 (0.49) HTR6QRFPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor HTR6, HTR1A, HTR1D HTR6 1/4885QRFPR 81/4885ERAP1 3485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.